CoreWeave reports Q3 revenue beat, targets 2028 profitability
Shares of CoreWeave jumped after its Q3 revenue beat and target for profitability in 2028.
Related stories
Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound
The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds
Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes.
M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC
Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm
Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial
At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm
Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo.
M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC
DUFFY: WE NEED L3HARRIS OR WHOEVER PROVIDED ROUTER TO DO A BETTER JOB
L impact | EQUITY | Nov 14, 2026, 04:32 PM UTC